Education
About Us
Working with TipRanks
Follow Us
OncoZenge AB (SE:ONCOZ)
:ONCOZ
Top Page
OncoZenge AB
(Frankfurt:ONCOZ)
41Neutral
OncoZenge AB (ONCOZ) vs. S&P 500 (SPY)
Market Cap
€62.78M
Dividend YieldN/A
Average Volume (3M)36.08K
Price to Earnings (P/E)―
Beta (1Y)2.02
Revenue GrowthN/A
EPS Growth45.38%
CountrySE
Employees1
SectorHealthcare
Sector Strength38
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding11,713,244
10 Day Avg. Volume30,594
30 Day Avg. Volume36,078
Financial Highlights & Ratios
PEG Ratio-1.08
Price to Book (P/B)7.09
Price to Sales (P/S)0.00
P/FCF Ratio-8.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
OncoZenge AB Business Overview & Revenue Model
Company DescriptionOncoZenge AB is a Swedish pharmaceutical company focused on the development and commercialization of innovative treatments for cancer. Leveraging advanced research in oncology, the company aims to address unmet medical needs by offering novel therapeutic solutions that improve patient outcomes. OncoZenge operates within the biotechnology and pharmaceutical sectors, concentrating on the development of proprietary drug formulations and delivery systems designed to enhance the efficacy and safety of cancer therapies.
How the Company Makes MoneyOncoZenge AB generates revenue primarily through the development and commercialization of its proprietary cancer treatments. The company may earn income from licensing agreements with other pharmaceutical companies, allowing them to market and distribute OncoZenge's products in various regions. Additionally, OncoZenge might engage in partnerships or collaborations with research institutions and industry peers to co-develop new therapies, potentially leading to shared revenues. The company may also seek funding through grants, research subsidies, or investment from private and public sources to support its research and development activities.
OncoZenge AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.00K | 3.00K | 0.00 | 0.00 | 0.00 | Gross Profit |
| 1.00K | 3.00K | 0.00 | 0.00 | 0.00 | EBIT |
| -8.68M | -15.90M | -43.57M | -4.89M | -801.00K | EBITDA |
| -6.31M | 7.27M | -43.57M | -4.89M | -801.00K | Net Income Common Stockholders |
| -8.69M | -15.90M | -46.65M | -3.89M | -636.00K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.86M | 12.63M | 29.14M | 51.22M | 10.00M | Total Assets |
| 11.43M | 20.34M | 36.89M | 85.23M | 38.30M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -3.86M | -12.63M | -29.14M | -51.22M | -10.00M | Total Liabilities |
| 1.48M | 1.70M | 2.92M | 4.90M | 9.01M | Stockholders Equity |
| 9.95M | 18.64M | 33.97M | 80.32M | 29.28M |
| Cash Flow | Free Cash Flow | |||
| -8.76M | -17.08M | -22.08M | -10.12M | -1.00K | Operating Cash Flow |
| -8.76M | -17.08M | -22.08M | -4.77M | -1.00K | Investing Cash Flow |
| 0.00 | 570.00K | 0.00 | -5.36M | 0.00 | Financing Cash Flow |
| 0.00 | 0.00 | 0.00 | 51.34M | 10.00M |
OncoZenge AB Technical Analysis
Positive
5.36
Price Trends
5.21
Positive
5.22
Positive
5.88
Negative
Market Momentum
-0.12
Negative
59.86
Neutral
85.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Positive. The current price of 5.36 is above the 20-day moving average (MA) of 4.50, above the 50-day MA of 5.21, and below the 200-day MA of 5.88, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 59.86 is Neutral, neither overbought nor oversold. The STOCH value of 85.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ONCOZ.
OncoZenge AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.15B | 3.05 | -44.13% | 2.84% | 16.42% | -0.48% | |
52 Neutral | €48.71M | ― | -47.01% | ― | -94.12% | -25.83% | |
42 Neutral | kr49.78M | ― | -152.99% | ― | ― | 58.36% | |
41 Neutral | €62.78M | ― | -59.73% | ― | ― | 45.38% | |
39 Underperform | €47.49M | ― | -96.58% | ― | 30.02% | -3985.71% | |
38 Underperform | kr67.03M | ― | -105.78% | ― | 58.72% | 70.69% | |
34 Underperform | €108.02M | ― | -82.34% | ― | ― | 35.61% |
* Healthcare Sector Average
Performance Comparison
SE:ONCOZ
OncoZenge AB
5.36
1.76
48.89%
SE:BIOSGN
Biosergen AB
0.46
0.16
54.55%
SE:COMBI
CombiGene AB
2.54
-0.74
-22.56%
SE:MODTX
Modus Therapeutics Holding AB
1.43
0.38
36.19%
SE:SPAGO
Spago Nanomedical AB
0.19
-0.05
-20.90%
SE:SPRINT
Sprint Bioscience AB
0.44
-0.79
-64.28%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.